Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of aprocitentan in resistant hypertension
CTR20261684Phase 3Active
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aprocitentan in resistant hypertension (RH), sponsored by CSPC Zhongnuo Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
aprocitentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on CTR20261684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261684.